Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Candidiasis Overview 8 Therapeutics Development 9 Pipeline Products for Candidiasis - Overview 9 Pipeline Products for Candidiasis - Comparative Analysis 10 Candidiasis - Therapeutics under Development by Companies 11 Candidiasis - Therapeutics under Investigation by Universities/Institutes 13 Candidiasis - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Candidiasis - Products under Development by Companies 18 Candidiasis - Products under Investigation by Universities/Institutes 21 Candidiasis - Companies Involved in Therapeutics Development 22 Amplyx Pharmaceuticals, Inc. 22 Bakker Medical Srl 23 Biomar Microbial Technologies 24 Cellceutix Corporation 25 Cidara Therapeutics, Inc. 26 Daewoong Pharmaceutical Co., Ltd. 27 General Biologicals Corporation 28 Grupo Ferrer Internacional, S.A. 29 Hsiri Therapeutics, LLC 30 Nanomerics Ltd 31 Novabiotics Limited 32 NovaDigm Therapeutics, Inc. 33 Onxeo SA 34 Panacela Labs, Inc. 35 Scynexis, Inc. 36 Sealife PHARMA GMBH 37 TGV-Laboratories 38 Viamet Pharmaceuticals, Inc. 39 Wellstat Vaccines, LLC 40 Candidiasis - Therapeutics Assessment 41 Assessment by Monotherapy Products 41 Assessment by Target 42 Assessment by Mechanism of Action 44 Assessment by Route of Administration 46 Assessment by Molecule Type 48 Drug Profiles 50 61894700 - Drug Profile 50 AC-17 - Drug Profile 51 amphotericin b - Drug Profile 52 amphotericin B - Drug Profile 53 amphotericin B - Drug Profile 54 APX-001 - Drug Profile 55 arasertaconazole - Drug Profile 56 Candida vaccine - Drug Profile 57 candidiasis vaccine - Drug Profile 58 CD-101 - Drug Profile 59 CTIX-1502 - Drug Profile 61 DWP-06081 - Drug Profile 62 Forazoline A - Drug Profile 63 KSL-W - Drug Profile 64 MH-010 - Drug Profile 65 miconazole nitrate - Drug Profile 66 Monoclonal Antibodies to Target Fba for Candidiasis - Drug Profile 67 mutanobactins - Drug Profile 68 Myc-102 - Drug Profile 69 NDV-3 - Drug Profile 70 NDV-3A - Drug Profile 72 NP-339 - Drug Profile 73 obliquumol - Drug Profile 74 PAC-113 - Drug Profile 75 pegylated amphotericin B - Drug Profile 77 PMX-1408 - Drug Profile 78 PMX-1570 - Drug Profile 80 PMX-1576 - Drug Profile 81 PMX-1591 - Drug Profile 82 PMX-1625 - Drug Profile 83 PMX-519 - Drug Profile 84 PMX-70004 - Drug Profile 85 Prof-002 - Drug Profile 86 Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile 87 SCY-078 - Drug Profile 89 SLP-0901 - Drug Profile 91 SLP-0904 - Drug Profile 92 Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile 93 Small Molecule for Fungal Infections - Drug Profile 94 Small Molecule for Systemic Candidiasis - Drug Profile 95 Small Molecules for Aspergillosis and Candidiasis - Drug Profile 96 Small Molecules for Candidiasis - Drug Profile 97 Small Molecules for Candidiasis - Drug Profile 98 Small Molecules for Candidiasis - Drug Profile 99 Small Molecules for Fungal Infections - Drug Profile 100 Small Molecules for Fungal Infections - Drug Profile 101 Synthetic Peptide for Multi-Drug Resistant Microbial Infections - Drug Profile 102 VT-1161 - Drug Profile 103 XELRYX-3 - Drug Profile 105 Candidiasis - Recent Pipeline Updates 106 Candidiasis - Dormant Projects 120 Candidiasis - Discontinued Products 124 Candidiasis - Product Development Milestones 125 Featured News & Press Releases 125 Appendix 132 Methodology 132 Coverage 132 Secondary Research 132 Primary Research 132 Expert Panel Validation 132 Contact Us 132 Disclaimer 133

List of Tables Number of Products under Development for Candidiasis, H1 2016 13 Number of Products under Development for Candidiasis - Comparative Analysis, H1 2016 14 Number of Products under Development by Companies, H1 2016 16 Number of Products under Investigation by Universities/Institutes, H1 2016 17 Comparative Analysis by Late Stage Development, H1 2016 18 Comparative Analysis by Clinical Stage Development, H1 2016 19 Comparative Analysis by Early Stage Development, H1 2016 20 Comparative Analysis by Unknown Stage Development, H1 2016 21 Products under Development by Companies, H1 2016 22 Products under Development by Companies, H1 2016 (Contd..1) 23 Products under Development by Companies, H1 2016 (Contd..2) 24 Products under Investigation by Universities/Institutes, H1 2016 25 Candidiasis - Pipeline by Amplyx Pharmaceuticals, Inc., H1 2016 26 Candidiasis - Pipeline by Bakker Medical Srl, H1 2016 27 Candidiasis - Pipeline by Biomar Microbial Technologies, H1 2016 28 Candidiasis - Pipeline by Cellceutix Corporation, H1 2016 29 Candidiasis - Pipeline by Cidara Therapeutics, Inc., H1 2016 30 Candidiasis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 31 Candidiasis - Pipeline by General Biologicals Corporation, H1 2016 32 Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H1 2016 33 Candidiasis - Pipeline by Hsiri Therapeutics, LLC, H1 2016 34 Candidiasis - Pipeline by Nanomerics Ltd, H1 2016 35 Candidiasis - Pipeline by Novabiotics Limited, H1 2016 36 Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H1 2016 37 Candidiasis - Pipeline by Onxeo SA, H1 2016 38 Candidiasis - Pipeline by Panacela Labs, Inc., H1 2016 39 Candidiasis - Pipeline by Scynexis, Inc., H1 2016 40 Candidiasis - Pipeline by Sealife PHARMA GMBH, H1 2016 41 Candidiasis - Pipeline by TGV-Laboratories, H1 2016 42 Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H1 2016 43 Candidiasis - Pipeline by Wellstat Vaccines, LLC, H1 2016 44 Assessment by Monotherapy Products, H1 2016 45 Number of Products by Stage and Target, H1 2016 47 Number of Products by Stage and Mechanism of Action, H1 2016 49 Number of Products by Stage and Route of Administration, H1 2016 51 Number of Products by Stage and Molecule Type, H1 2016 53 Candidiasis Therapeutics - Recent Pipeline Updates, H1 2016 110 Candidiasis - Dormant Projects, H1 2016 124 Candidiasis - Dormant Projects (Contd..1), H1 2016 125 Candidiasis - Dormant Projects (Contd..2), H1 2016 126 Candidiasis - Dormant Projects (Contd..3), H1 2016 127 Candidiasis - Discontinued Products, H1 2016 128 List of Figures Number of Products under Development for Candidiasis, H1 2016 13 Number of Products under Development for Candidiasis - Comparative Analysis, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Number of Products under Investigation by Universities/Institutes, H1 2016 17 Comparative Analysis by Clinical Stage Development, H1 2016 19 Comparative Analysis by Early Stage Products, H1 2016 20 Assessment by Monotherapy Products, H1 2016 45 Number of Products by Targets, H1 2016 46 Number of Products by Stage and Targets, H1 2016 46 Number of Products by Mechanism of Actions, H1 2016 48 Number of Products by Stage and Mechanism of Actions, H1 2016 48 Number of Products by Routes of Administration, H1 2016 50 Number of Products by Stage and Routes of Administration, H1 2016 50 Number of Products by Molecule Types, H1 2016 52 Number of Products by Stage and Molecule Types, H1 2016 52

Amplyx Pharmaceuticals, Inc. Bakker Medical Srl Biomar Microbial Technologies Cellceutix Corporation Cidara Therapeutics, Inc. Daewoong Pharmaceutical Co., Ltd. General Biologicals Corporation Grupo Ferrer Internacional, S.A. Hsiri Therapeutics, LLC Nanomerics Ltd Novabiotics Limited NovaDigm Therapeutics, Inc. Onxeo SA Panacela Labs, Inc. Scynexis, Inc. Sealife PHARMA GMBH TGV-Laboratories Viamet Pharmaceuticals, Inc. Wellstat Vaccines, LLC